D. E. Shaw & Co. Inc. Buys 316,100 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

D. E. Shaw & Co. Inc. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 87.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 678,234 shares of the biopharmaceutical company’s stock after acquiring an additional 316,100 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 1.19% of Agios Pharmaceuticals worth $29,245,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of AGIO. Norges Bank bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $6,826,000. Allianz Asset Management GmbH lifted its stake in Agios Pharmaceuticals by 38.8% in the fourth quarter. Allianz Asset Management GmbH now owns 149,111 shares of the biopharmaceutical company’s stock valued at $3,321,000 after acquiring an additional 41,701 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at $951,000. NEOS Investment Management LLC bought a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at about $210,000. Finally, Rafferty Asset Management LLC increased its stake in shares of Agios Pharmaceuticals by 14.9% during the 4th quarter. Rafferty Asset Management LLC now owns 153,485 shares of the biopharmaceutical company’s stock worth $3,418,000 after purchasing an additional 19,861 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AGIO. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. Finally, The Goldman Sachs Group increased their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research report on Tuesday, June 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and an average price target of $52.50.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $45.61 on Friday. The stock has a market capitalization of $2.59 billion, a P/E ratio of -7.22 and a beta of 0.75. The stock’s fifty day moving average is $45.68 and its 200 day moving average is $39.74. Agios Pharmaceuticals, Inc. has a 52 week low of $19.80 and a 52 week high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. Agios Pharmaceuticals’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.51) earnings per share. Equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -4.85 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.